Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin in Metastatic Castration-Resistant Prostate Cancer
NCT04754191Phase 2Active, not recruiting
- Sponsor
- University of Utah
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Utah. Primary endpoint: Proportion of subjects achieving a protocol-defined response at 12 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04754191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04754191.